8-K: XOMA Corp to Receive $8.1 Million from Day One Biopharma Priority Review Voucher Sale

XOMA Corporation is set to receive $8.1 million following Day One Biopharmaceuticals' sale of a priority review voucher.

Summary

• XOMA Corporation will receive $8.1 million from Viracta Therapeutics as a result of Day One Biopharmaceuticals selling a priority review voucher for $108 million.
• The priority review voucher was awarded to Day One after the FDA approved their drug OJEMDA (tovorafenib).
• XOMA had previously acquired the rights to potential milestones, royalties, and a share of event-based economics related to tovorafenib from Viracta in March 2021.

Sentiment

Score: 8

Explanation: The document indicates a positive financial event for XOMA with a significant payment, suggesting a favorable outlook.

Positives

• XOMA will receive a significant payment of $8.1 million, boosting its financials.
• The sale of the priority review voucher validates the potential value of the tovorafenib asset.

Risks

• The payment is dependent on the agreement between XOMA and Viracta, and any issues with this agreement could impact the payment.
• Future payments related to tovorafenib are dependent on milestones and royalties, which are not guaranteed.

Future Outlook

XOMA is positioned to receive future payments based on milestones and royalties associated with tovorafenib.

Industry Context

The sale of a priority review voucher is a common mechanism in the pharmaceutical industry to monetize regulatory approvals, and this event highlights the value of such assets.

Comparison to Industry Standards

• Priority review vouchers are often sold for significant amounts, with prices varying based on the therapeutic area and market potential.
• The $108 million sale by Day One is within the typical range for such vouchers, indicating a strong market for these assets.
• Other companies such as BioMarin and Sarepta have also sold priority review vouchers in the past, with prices ranging from $80 million to $130 million.

Stakeholder Impact

• Shareholders will likely view this as a positive development, as it increases the company's cash position.
• The payment could potentially fund further research and development activities.

Key Dates

Keywords

priority review voucher, tovorafenib, XOMA Corporation, Day One Biopharmaceuticals, Viracta Therapeutics, milestones, royalties, FDA approval, OJEMDA